Trending...
- "Leading From Day One: The Essential Guide for New Supervisors" Draws from 25+ Years of International Management Experience - 357
- New Slotozilla Project Explores What Happens When the World Goes Silent - 287
- City of Long Beach Launches Second Cohort of Urban Planning and Design Internship Program - 255
A novel vascular disruptive antioxidant agent for treating wet and dry AMD with potential synergy given concurrent therapies
RIVERSIDE, Calif. - Californer -- RIVERSIDE, CA – Citrus Therapeutics, LLC, a manufacturer of innovative therapies and an early leader in novel multi-pharmacophore agents for AMD treatment, announces that the U.S. Patent Office has issued Patent Application No. 17/837,917 for the "Therapeutic Agent for Treatment of Age-Related Macular Degeneration" and for the registration of the trade name "CTZ1™", the first-of-its-kind vascular disruptive agent (VDA) for treating both wet and dry AMD.
CTZ1™ is a unique vascular disruptive agent for combating the oxidative damage encountered in macular degeneration. CTZ1™ combines an antioxidant carbazole moiety fused to a nicotine analog; this multi-pharmacophore combination mitigates oxidant damage experienced in AMD. As a Vascular Disruptive Agent, CTZ1™ can stabilize and temper pathological angiogenic processes secondary to progressive AMD.
More on The Californer
CTZ1™ is currently being developed with potential as a topical (i.e., eye drop solution) and local (i.e., intravitreal) therapy.
CTZ1 is a lead candidate for the treatment of neovascular age-related macular degeneration. To learn more about CTZ1™ as a therapeutic agent, visit our website here: citrustherapeutics.com or email salkayali@citrustherapeutics.com
CTZ1™ debuts from Citrus Therapeutics, LLC, based in Riverside, California. Citrus Therapeutics is owned and operated by Eric Chin MD, David Almeida MD MBA PhD, and Mr. Ahmad Alkayali, inventor. Citrus Therapeutics, LLC was formed to develop, research, and promote innovative multi-pharmacophore therapies.
David RP Almeida, MD MBA PhD, is a Board-Certified Ophthalmologist and Vitreoretinal Surgeon. Dr. Almeida is involved in diagnosing and treating conditions of the vitreous, retina, and macula. Dr. Almeida is Director of Clinical Research at Erie Retina Research and Medical Director for Ophthalmology Research at The Clinical Trials Network. Dr. Almeida is Chief Medical Editor of the online publication Eyes on Eyecare, ophthalmology division.
More on The Californer
Eric K. Chin, M.D., Board-Certified ophthalmologist, is a graduate of the University of California Berkeley and Chicago Medical School. Dr. Chin was awarded several accolades for teaching and research on treatments for various retinal diseases. Dr. Chin is a partner at Retina Consultants of Southern California and serves as Clinical Faculty at Loma Linda University and Loma Linda Veterans Affairs Hospital.
Mr. Ahmad Alkayali is a renowned and trusted leader in developing and manufacturing natural ingredients for foods, beverages, and supplements. Mr. Alkayali is the original inventor of three Collagen Type II patents for dietary supplements and the first to introduce Collagen Types I, II, and III food supplements to the Health Food Industry more than 35 years ago. Mr. Alkayali's inventions and elements are incorporated into nutritional products that are recognized globally for cardiovascular, joint, skin, anti-aging, and eye health.
CTZ1™ is a unique vascular disruptive agent for combating the oxidative damage encountered in macular degeneration. CTZ1™ combines an antioxidant carbazole moiety fused to a nicotine analog; this multi-pharmacophore combination mitigates oxidant damage experienced in AMD. As a Vascular Disruptive Agent, CTZ1™ can stabilize and temper pathological angiogenic processes secondary to progressive AMD.
More on The Californer
- California prepares state resources ahead of heavy rain, dry lightning, and increased fire threats
- California: Governor Newsom's expanded CHP deployment makes early impact on crime, seizing drugs and illegal guns
- California: Governor Newsom honors fallen Caltrans worker
- READY Long Beach Returns October 12
- California: Governor Newsom proclaims Preparedness Month
CTZ1™ is currently being developed with potential as a topical (i.e., eye drop solution) and local (i.e., intravitreal) therapy.
CTZ1 is a lead candidate for the treatment of neovascular age-related macular degeneration. To learn more about CTZ1™ as a therapeutic agent, visit our website here: citrustherapeutics.com or email salkayali@citrustherapeutics.com
CTZ1™ debuts from Citrus Therapeutics, LLC, based in Riverside, California. Citrus Therapeutics is owned and operated by Eric Chin MD, David Almeida MD MBA PhD, and Mr. Ahmad Alkayali, inventor. Citrus Therapeutics, LLC was formed to develop, research, and promote innovative multi-pharmacophore therapies.
David RP Almeida, MD MBA PhD, is a Board-Certified Ophthalmologist and Vitreoretinal Surgeon. Dr. Almeida is involved in diagnosing and treating conditions of the vitreous, retina, and macula. Dr. Almeida is Director of Clinical Research at Erie Retina Research and Medical Director for Ophthalmology Research at The Clinical Trials Network. Dr. Almeida is Chief Medical Editor of the online publication Eyes on Eyecare, ophthalmology division.
More on The Californer
- Snell & Wilmer Attorneys Keith Gregory & Dana Ontiveros Recognized as 2025 Leaders of Influence
- Teamsters Demand Fair Deal at Ralphs
- Entry Level Acting in LA 2025 Workbook to be Released in West Hollywood, California USA 2pm 10/11/25
- One Park Financial Earns Great Place to Work® Certification for the Eighth Time
- Los Angeles Affordable Healthcare Provider CCHC Reminds Families to Prioritize Vaccines and Wellness for Back-to-School Season
Eric K. Chin, M.D., Board-Certified ophthalmologist, is a graduate of the University of California Berkeley and Chicago Medical School. Dr. Chin was awarded several accolades for teaching and research on treatments for various retinal diseases. Dr. Chin is a partner at Retina Consultants of Southern California and serves as Clinical Faculty at Loma Linda University and Loma Linda Veterans Affairs Hospital.
Mr. Ahmad Alkayali is a renowned and trusted leader in developing and manufacturing natural ingredients for foods, beverages, and supplements. Mr. Alkayali is the original inventor of three Collagen Type II patents for dietary supplements and the first to introduce Collagen Types I, II, and III food supplements to the Health Food Industry more than 35 years ago. Mr. Alkayali's inventions and elements are incorporated into nutritional products that are recognized globally for cardiovascular, joint, skin, anti-aging, and eye health.
Source: Citrus Therapeutics
Filed Under: Health
0 Comments
Latest on The Californer
- TSWHZC Platform Combines Automated Portfolio Management with Proof of Reserves for Brazil Market Entry
- AureaVault Positions Digital Asset Infrastructure for Shifting Monetary Policy Environment
- JQRBT Unveils High-Speed Trading Infrastructure Designed for Growing Institutional Crypto Market
- TOM HAUSKEN: The Space Between
- California: Governor Newsom announces appointments 9.17.25
- Marketing Maven Ranked Top 10 PR Firm in Los Angeles by O'Dwyer's in 2025 Rankings Report
- California Lutheran University Receives Over $2.9 Million in Grant Funding
- Nationwide Boiler Supplies In-Stock 200K lb/hr Ultra Low NOx Boiler Package for Recovery Efforts i
- Ventura College Foundation Accepting Scholarship Applications for 2026-27 School Year
- C3.ai, Inc. (AI) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
- California: Governor Newsom proclaims Constitution Day and Citizenship Day
- California: Governor Newsom signs legislation 9.17.25
- New Leadership and Renovations Usher in Next Chapter for Sunrise Manor
- Following Trump's politicization of CDC, West Coast states issue unified vaccine recommendations — California breaks from future federal guidance with new law
- Who Will Win the 2025 WNBA Finals? OddsTrader Shares Live Betting Odds and Projections
- Silva Construction Weighs In on the Most Popular Home Design Trends for 2026
- Geeks5g Creative Marketing: The Powerhouse Behind Business Growth
- Wise Business Plans Now Serves Entrepreneurs in Los Angeles with Tailored Business Plan Writing
- Proposition 1 continues delivering support for vulnerable homeless populations in California
- Agemin Unveils Breakthrough AI Model for Biometric Age Estimation, Setting New Standards in Online Child Safety